Table 1. Differences in treatment approaches for limited-stage small cell esophageal cancer between China and the United States.
| Characteristics | China | SEER | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All (n=483) | S (n=141) | NCT (n=171) | CRT (n=171) | P | All (n=128) | S (n=17) | NAT (n=12) | CRT (n=67) | CT (n=26) | RT (n=6) | P | ||
| Sex | 0.80 | 0.12 | |||||||||||
| Female | 136 | 41 (30.1) | 50 (36.8) | 45 (33.1) | 42 | 4 (9.5) | 2 (4.8) | 20 (47.6) | 14 (33.3) | 2 (4.8) | |||
| Male | 347 | 100 (28.8) | 121 (34.9) | 126 (36.3) | 86 | 13 (15.1) | 10 (11.6) | 47 (54.7) | 12 (14.0) | 4 (4.7) | |||
| Age, years | 0.01 | 0.03 | |||||||||||
| ≤60 | 212 | 61 (28.8) | 89 (42.0) | 62 (29.2) | 36 | 5 (13.9) | 8 (22.2) | 17 (47.2) | 6 (16.7) | 0 (0.0) | |||
| >60 | 271 | 80 (29.5) | 82 (30.3) | 109 (40.2) | 92 | 12 (13.0) | 4 (4.3) | 50 (54.3) | 20 (21.7) | 6 (6.5) | |||
| Tumor location | 0.45 | 0.01 | |||||||||||
| Proximal/middle third | 329 | 101 (30.7) | 111 (33.7) | 117 (35.6) | 52 | 8 (15.4) | 2 (3.8) | 27 (51.9) | 15 (28.8) | 0 (0.0) | |||
| Distal third | 154 | 40 (26.0) | 60 (39.0) | 54 (35.1) | 61 | 8 (13.1) | 9 (14.8) | 33 (54.1) | 9 (14.8) | 2 (3.3) | |||
| Unknown | 0 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 15 | 1 (6.7) | 1 (6.7) | 7 (46.7) | 2 (13.3) | 4 (26.7) | |||
| T stage | <0.001 | 0.15 | |||||||||||
| T1/2 | 202 | 74 (36.6) | 78 (38.6) | 50 (24.8) | 29 | 5 (17.2) | 2 (6.9) | 13 (44.8) | 7 (24.1) | 2 (6.9) | |||
| T3/4 | 281 | 67 (23.8) | 93 (33.1) | 121 (43.1) | 32 | 4 (12.5) | 4 (12.5) | 22 (68.8) | 1 (3.1) | 1 (3.1) | |||
| Unknown | 0 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 67 | 8 (11.9) | 6 (9.0) | 32 (47.8) | 18 (26.9) | 3 (4.5) | |||
| N stage | <0.001 | 0.64 | |||||||||||
| N0 | 174 | 57 (32.8) | 76 (43.7) | 41 (23.6) | 20 | 3 (15.0) | 2 (10.0) | 13 (65.0) | 1 (5.0) | 1 (5.0) | |||
| N+ | 309 | 84 (27.2) | 95 (30.7) | 130 (42.1) | 11 | 1 (9.1) | 2 (18.2) | 6 (54.5) | 2 (18.2) | 0 (0.0) | |||
| Unknown | 0 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 97 | 13 (13.4) | 8 (8.2) | 48 (49.5) | 23 (23.7) | 5 (5.2) | |||
Data are presented as n (%). S, upfront surgery; SEER, Surveillance, Epidemiology, and End Results; S, upfront surgery; NCT, neoadjuvant chemotherapy; CRT, chemoradiotherapy; NAT, neoadjuvant therapy; CT, chemotherapy; RT, radiotherapy.